Possible Mechanisms of Green Tea and Its Constituents against Cancer

Yohei Shirakami 1,2,* and Masahito Shimizu 1

1 Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan; shimim-gif@umin.ac.jp
2 Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
* Correspondence: ys2443@gifu-u.ac.jp; Tel.: +81-58-230-6308

Received: 31 July 2018; Accepted: 5 September 2018; Published: 7 September 2018

Abstract: A number of epidemiological, clinical, and experimental researches have indicated that administration of green tea appears to have anti-cancer activity. According to findings of laboratory cell culture studies, a diverse mechanism has been observed underlying the effects of green tea catechins against cancer. These mechanisms include anti-oxidant activity, cell cycle regulation, receptor tyrosine kinase pathway inhibition, immune system modulation, and epigenetic modification control. This review discusses the results of these studies to provide more insight into the effects of green tea administration on cancers observed to date in this research field.

Keywords: catechin; green tea; cancer; chemoprevention; receptor tyrosine kinase

1. Introduction

One of the most widely consumed beverages in the world, tea, has been taken since ancient times, with tea leaves originally used for medicine [1,2]. Produced from leaves of the plant *Camellia sinensis*, tea is usually categorized into three types—green, black, and oolong—due to leaf processing. Green tea is produced by drying and steaming tea leaves to prevent fermentation, while tea leaves for black or Oolong teas are totally or partially fermented, respectively [3,4]. Among teas, over 70% is black tea, which is commonly consumed in western countries, and approximately 20% is green tea consumed primarily in Asia and the Middle East [5]. Green tea has been most extensively investigated for its health advantages.

Tea contains polyphenols, which are crucial constituents, including catechins and flavonoids. Green tea possesses high quantities of green tea catechins (GTCs) in comparison with other types of tea [6]. Among the major catechins in green tea, such as (−)-epigallocatechin-3-gallate (EGCG), (−)-epicatechin-3-gallate (ECG), (−)-epigallocatechin (EGC), and (−)-epicatechin (EC), EGCG is the most plentiful being approximately 70% of the entire catechin constituent [7].

Currently, tea constituents, especially GTCs, have been the focus of scientists because of their possible preventive and therapeutic effects on chronic diseases, including cardiovascular disease, metabolic syndrome, and malignancy. GTCs have also been reported to exert beneficial actions against diabetes mellitus, stroke, Parkinson’s disease, and Alzheimer’s disease [8–11]. A number of epidemiological studies have shown that drinking green tea provides beneficial effects on human health and that tea consumption is associated with decreased incidence of various chronic diseases, including cancers, although the evidence is inconclusive [12–15]. Numerous cell culture and animal examinations have demonstrated that diverse actions exert the cancer preventive and therapeutic effects of EGCG as well as green tea. The mechanisms include stimulation of anti-oxidant activity [16,17], alteration of the...
cell-cycle [18] and DNA methyltransferase [19], and suppression of mitogen-activated protein kinase (MAPK) and receptor tyrosine kinase (RTK) pathways [20,21].

This review aims to provide more insight into the effects and mechanisms of tea catechins, especially GTCs, against cancer, and to discuss the current research investigating the effects of GTCs on cancer development and possible mechanisms underlying of how they act as anti-cancer agents.

2. Anti-Cancer Action of Green Tea and Its Contents

In laboratory examinations as well as chemically- or genetically-induced carcinogenesis models in rodents, tea constituents and GTCs have been shown to exert anti-cancer action. Researchers have examined the effects on various cancer types, including skin, lung, oral cavity, esophagus, stomach, small and large intestine, liver, pancreas, mammary gland, bladder, and prostate cancer [9,22–24]. The following sections will state the mechanisms which may underlie the anti-cancer activity of GTCs in several organ sites mentioned above.

Treatment of human small-cell lung cancer cells with EGCG was found to lead to reduced activity of telomerase and decreased caspase-3 and -9 activities [25]. Similarly, the proliferation of non-small cell lung cancer (NSCLC) cell was inhibited by EGCG treatment [26,27]. One of these was observed in cell lines that were both sensitive and resistant to erlotinib, a molecularly targeted agent for lung cancer treatment [26]. A study examining the efficacy of erlotinib and/or EGCG revealed that combination treatment contributed to significant inhibition of cell proliferation, colony formation, and growth of NSCLC xenografts in comparison to treatment with either agent alone [26]. Other studies have also demonstrated that the development of chemically-induced lung cancer in several rodent models was suppressed markedly by green tea supplementation [28–32]. The standardized polyphenol, named Polyphenon E (PolyE), contains EGCG, other catechins, and caffeine, extracted from green tea. Administration of PolyE markedly decreased incidence and number of lung adenocarcinoma, [28,29] and progression of lung adenoma into adenocarcinoma in mice. Gene expression changes in a chemically-induced mouse lung cancer model were further examined, identifying over 80 genes that were differentially expressed in tumors, but not in normal tissues, and were reversed by GTCs administration [29].

Previous studies indicated that signal transductions of cell-surface receptor pathways were inhibited by EGCG in MDA-MB-231 human breast cancer cells, contributing to the reduced production of vascular endothelial growth factor (VEGF) [33,34]. A relation of EGCG with VEGF was also investigated in another study, where cell viability and angiogenesis were inhibited, and apoptosis was induced by EGCG treatment via reduced VEGF expression in MDA-MB-231 cells [35]. A similar study demonstrated that treatment with green tea polyphenols or EGCG suppressed breast cancer cell proliferation via inhibition of cell growth and induction of apoptosis [36–39]. In chemically induced mammary tumorigenesis models, treatment with GTCs decreased the incidence, multiplicity, and volume of mammary tumors [40–42].

The effects of EGCG on colorectal cancer have also been closely investigated. As well as the study indicating that EGCG suppressed the growth of HT-29 human colon cancer cells [43], our research group reported that either EGCG or PolyE preferentially inhibited the growth of various human colorectal cancer cells, including SW480, SW837, HCT116, and HT29, compared to normal human colon cells [44]. The growth of xenografts inoculated with the SW837 cell was also markedly suppressed by EGCG administration [45]. In studies using animal models of colorectal carcinogenesis, green tea administration was found to suppress the development of aberrant crypt foci (ACF), pre-malignant lesions in colorectum [46,47]. In our study, it was shown that EGCG or PolyE supplementation inhibited inflammation-related colorectal carcinogenesis in mice induced by azoxymethane (AOM) plus dextran sodium sulfate (DSS) [48]. This experimental mouse study is considered a model for colorectal cancer caused by chronic intestinal inflammation that mimics inflammatory bowel diseases, such as ulcerative colitis and Crohn’s disease. In addition, our group also indicated that EGCG supplementation decreased the development of ACF and β-catenin-accumulated crypts (BCACs),
an additional type of premalignant lesion in the colorectum, in male C57BL/KsJ-db/db mice, a genetically-engineered animal model to exhibit obesity and type 2 diabetes mellitus [49].

In LNCaP human prostate cancer cells, EGCG induced apoptosis via modulation of intrinsic and extrinsic pathways [50]. Studies employing xenograft of prostate cancer cells exhibited decreased xenograft tumor growth with the administration of green tea extracts or polyphenols [51–53]. In a study employing a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, researchers observed that supplementation of the polyphenol extracted from green tea markedly suppressed the incidence of the prostate tumor [54]. Inhibitory effects of oral GTCs infusion on the formation of the prostate tumor were also observed in a similar mouse model [55].

3. Possible Mechanisms of Action of Green Tea Catechins against Cancer

EGCG, GTCs have been extensively investigated to reveal their anti-cancer mechanisms. A variety of mechanisms by which GTCs or EGCG display their biological activity in cancer cells and malignancies have been hypothesized. Several of them are stated in the following sections, and possible mechanisms of the action of GTCs against malignancy are summarized in Figure 1 and Table 1.

![Figure 1. Possible mechanisms of green tea catechins against cancer.](image)

3.1. Anti-Oxidant and Pro-Oxidant Activities

The anti-oxidant ability of GTCs has been well demonstrated. Catechins possess anti-oxidant abilities by neutralizing free radicals. Among tea GTCs, ECG has the greatest potency as a radical scavenger, followed by EGCG, EGC, and EC [56,57]. A previous study indicated that GTCs exert a strong anti-oxidant function through quenching free radical species and chelating transition metals [16]. The anti-oxidant action is attributable to the presence of phenolic groups with sensitivity to oxidation which is able to generate quinine. The activity is further enhanced due to the trihydroxyl structure in the D-ring [16,58,59]. Although GTCs are believed to function as powerful radical scavengers, their anti-oxidant activities in animal models and human subjects are not conclusive.

The direct anti-oxidant activity of tea catechins was found primarily under conditions of increased oxidative stress, such as in patients with ulcerative colitis and hepatitis [16]. In an animal study, EGCG treatment attenuated lipid peroxidation and protein carbonylation in the livers of aged rats [60]. Interventional studies examining the anti-oxidant effects of green tea intake reported interesting results. Regular consumption of 600 to 1500 mL/day green tea increased the anti-oxidant ability in plasma and
protected healthy subjects from DNA damage. The studies, however, demonstrated limited ex vivo and in vivo evidence that green tea intake provided anti-oxidant activity in cancer prevention [61], suggesting that green tea administration may display anti-cancer effects only in condition with excess oxidative stress.

On the other hand, the pro-oxidant activity of green tea polyphenols has also been reported and are well summarized in a previous paper by Lambert and Elias [16]. GTCs can generate reactive oxygen species (ROS), which are essential for the induction of apoptosis and lead to the inhibition of cancer cell growth [11,16]. Both anti- and pro-oxidant activities of GTCs are thought to be important against malignancy, especially for cancer prevention, and to play roles in different aspects of the oncogenic process [16].

3.2. Induction of Apoptosis and Cell Cycle Arrest

Apoptosis is considered a programmed cell death and is hypothesized to exert an important role in eliminating cancerous cells and to act as a protective mechanism against the development of malignancy [62]. Studies have shown that EGCG treatment induced apoptosis due to the generation of ROS and caspase-3 and -9 activations, leading to cell-cycle arrest at G1 phase via controlling expressions of cyclin D1, cdk4, and p21CIP1 [11,63]. In human head and neck squamous carcinoma (HNSCC) cell lines, EGCG treatment increased the proportion of G1 phase, decreased cyclin D1 protein levels, and increased p21CIP1 and p27KIP1 protein levels [64]. Other researchers reported that EGCG reduced Bcl-2 and Bcl-xL protein levels and increased Bax with caspase-3 activation [65]. In a human colon cancer cell, treatment with either EGCG or PolyE was observed to increase the ratio of cells in the G1 phase and to induce apoptosis. The treatment also decreased cyclin D1 and Bcl-xL proteins and increased caspase-3 and -9 activities [44].

In a colorectal carcinogenesis model employing obese and diabetic mice and carcinogen AOM, EGCG administration suppressed the development of pre-cancerous lesions in the colorectum and significantly decreased cyclin D1 levels in the colonic mucosa of mice [49]. The results suggest that green tea and the contents exert anti-cancer activity by regulating cell cycle arrest and inducing apoptosis through diverse mechanisms.

3.3. Inhibition of NK-κB and AP-1

A transcriptional factor nuclear factor-κB (NF-κB) is known to play a vital role in inhibiting apoptosis in cancer cells, leading to carcinogenesis [66]. Previous examinations demonstrated that EGCG treatment inhibited NF-κB activation in human HNSCC, breast cancer, and lung cancer cells [33,67]. When NF-κB is activated, it is translocated into the nucleus, which leads to diverse gene expression associated with carcinogenesis and tumor progression, including cellular transformation, proliferation, invasion, metastasis, radio-resistance, chemo-resistance, and inflammation. In human colon cancer and epidermoid carcinoma cells, NF-κB activity and its nuclear translocation were also inhibited by EGCG [18,68].

Another transcription factor activator protein-1 (AP-1) regulates gene expression levels related to apoptosis and cellular proliferation. It is considered that AP-1 promotes proliferation through up-regulation of cyclin D1 gene expression and down-regulation of tumor-suppressor genes, such as p53 and p21CIP1 [68]. EGCG was reported to suppress AP-1 activation and cell transformation and to inhibit Ras-activated AP-1 in a mouse epidermal cell line [69,70]. Studies by our research group in a human colon cancer cell line revealed that EGCG inhibited transcriptional activities of AP-1 and NF-κB promoters, as examined by reporter assay and that treatment with either EGCG or PolyE caused inhibition of AP-1 and NF-κB luciferase reporter activities [44,71]. These findings suggest that inhibiting NF-κB and AP-1 pathways is one of the important mechanism underlying the anti-cancer activity of GTCs.
3.4. Inhibition of Receptor Tyrosine Kinase Pathways

Previous studies have shown that receptor tyrosine kinases (RTKs) play pivotal roles in cellular proliferation and apoptosis and are proposed targets by GTCs for cancer prevention [72,73]. RTKs and their downstream signals, including the Ras/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways, regulate the expression levels of various target genes associated with proliferation and apoptosis [74,75]. Binding of cytokines and growth factors as specific ligands to the extracellular domain of RTKs activates intrinsic tyrosine kinase and induces phosphorylation of tyrosine residues, leading to the creation of docking sites for downstream targets [74,75]. In this manner, activation of cell-surface RTKs and downstream signaling pathways fulfill roles in the modulation of various essential processes.

Pre-cancerous or cancer cells frequently display inappropriate or constitutive activation of RTKs through mutation and over-expression of various genes [76,77]. The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors, a subfamily of four closely related RTKs: EGFR (ErbB-1), human epidermal growth factor receptor (HER) 2/neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4). Insulin-like growth factor-1 receptor (IGF-1R) and VEGF receptor (VEGFR) belong to a separate family of RTKs. Irregularities in some RTKs, especially EGFR, VEGFR2, and IGF-1R, are deeply associated with the properties of malignancy [76,77]. These findings indicate that RTKs, such as EGFR and HER2, are targets in the prevention and therapy of malignancies. In practice, RTK modulators are used for the treatment of various types of cancer, including lung, breast, stomach, and colon cancer [78].

It has been reported that GTCs affect RTKs in a beneficial manner. Several studies reported anti-cancer effects of EGCG on the VEGF/VEGFR axis. EGCG treatment suppressed VEGF production via inhibiting activation of signal transducer and activator of transcription (STAT)-3 and NF-κB in human HNSCC and breast cancer cells [33]. In another study, EGCG treatment inhibited phosphorylation of VEGFRs and induced apoptosis in lymphocytic leukemia cells [79]. Our research group also indicated that EGCG suppressed the growth of tumor xenografts generated from human colon cancer and hepatoma cells by down-regulating VEGFR2, Akt, and ERK activation and VEGF expression [45,80].

Focusing on IGF/IGF-1R signaling, in vitro treatment with EGCG reduced IGF-1 and the activated form of IGF-1R levels and increased IGFBP-3 in human hepatoma and colon cancer cells, indicating that EGCG exhibited inhibitory actions on the IGF/IGF-1R axis [81,82]. As described above, in the study using TRAMP mice, administration of green tea polyphenols in drinking water inhibited prostate cancer development and its metastatic lesions [54]. This treatment was considered to reduce IGF-1 levels and to recover IGF-binding protein-3 (IGFBP-3) levels through reduced PI3K and phosphorylated ERK and Akt levels [54,83]. Our research group also reported similar experimental results in which colorectal pre-malignant lesions were significantly suppressed by drinking water containing EGCG in a mouse colorectal carcinogenesis model [49].

Studies indicated that EGCG treatment inhibited EGFR and HER2 activation and decreased activation of their downstream signaling pathways in HNSCC, colorectal cancer, and breast cancer cell lines [33,34,44,64] as well as HER3 activation [71]. The research group also observed that EGCG and PolyE treatment decreased EGFR and HER2 phosphorylation and led to a subsequent decrease in ERK and Akt phosphorylation [44].

Due to these observations, RTKs are thought to be promising targets of EGCG for its anti-cancer activity. In particular, “lipid rafts”, known as detergent-insoluble plasma membrane domains, were considered to exert important roles for signal processing of RTKs. It was found that the lipid organization on the plasma membrane was altered by EGCG followed by EGFR internalization into endosomes, which prevented ligands from binding to EGFR [84,85]. The EGFR degradation following internalization was induced by phosphorylation of the receptor at serine 1046/1047, which is associated with EGCG-mediated p38 MAPK activation [86]. This effect of EGCG on EGFR degradation appears to account for ubiquitous action to modulate RTKs on lipid rafts.
3.5. Modulation of Immune System

The immune system functions to fight against unusual conditions or abnormal agents in the body to prevent diseases, including cancer [87]. Green tea has been reported to enhance humoral and cell-mediated immunity, resulting in decreased risk of several cancers [88]. Inflammation is considered as one of the immune system responses, but inappropriate inflammation frequently causes various diseases. EGCG is known to have a strong anti-inflammatory effect with therapeutic potential, and a large number of in vivo studies found that green tea polyphenols administration attenuated inflammation.

Among the examinations, one found that administration of green tea polyphenols reduced the level of tumor necrosis factor (TNF) induced by lipopolysaccharide [89]. Similarly, our research group demonstrated that EGCG and PolyE administration decreased levels of several inflammatory cytokines, including TNF, in the colorectal epithelium and suppressed inflammation-related carcinogenesis in a mouse colorectal cancer model [48]. These observations suggest that GTCs administration may possess a favorable efficacy on inflammatory disorders through anti-inflammatory activity and inhibiting NF-κB activation [22].

A tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) is thought to suppress effector T cell immunity and to play a pivotal role in inducing immune tolerance [90]. In human oral cancer cell lines, EGCG was found to markedly inhibit the expression of IDO [91]. The effects of EGCG on IDO expression were examined, which revealed that EGCG markedly decreased expression levels of interferon (IFN)-γ-induced IDO and its enzymatic activity in colon cancer cells [92]. The same research group investigated the effects of an IDO inhibitor 1-methyltryptophan (1-MT) and EGCG on colorectal carcinogenesis. The study demonstrated that either 1-MT or EGCG significantly attenuated IDO activity in serum and suppressed IDO-overexpressing pre-neoplastic lesions in the colorectum of an AOM-induced rat colon cancer model [93]. The observations above indicate that EGCG appears to exert inhibitory effects on cancers by suppressing IDO expression and function, suggesting that IDO-inhibiting agents, including EGCG, have the potential for immunomodulation against malignancy.

3.6. Epigenetic Alteration

Epigenetics is the reversible heritable alterations of gene expression, which occur without DNA sequence alteration. These changes exert significant roles in the regulation of general gene expressions and contribute to cancer development due to affecting histone modification, altering chromatin structure, and regulating non-coding microRNA expression [94]. Epigenetic silencing of DNA-repair and tumor-suppressor genes, which usually results from gene hypermethylation in the early stages of cancer, is often related to various diseases [95].

EGCG has been reported to alter epigenetics in cancer cells through histone modification as well as DNA methylation [96,97]. It was reported that EGCG suppressed DNA methyltransferase activation, leading to cytosine-phosphate-guanine demethylation and to the subsequent restoration of silenced tumor-suppressor genes, including retinoic acid receptor-β (RARβ), p16INK4a, and O6-methylguanine-DNA methyltransferase [98]. Other in vitro examinations revealed that EGCG treatment promoted partial demethylation for reactivation of hypermethylated RARβ in breast cancer cells, as well as decreased methylation of telomerase reverse transcriptase promoter [94,99]. There have been, however, other studies in which EGCG treatment had no significant effects on epigenetic alteration, including demethylation or the restoration of methylation-silenced genes. In addition, the observations of in vivo studies investigating the effects of EGCG on the reversal of hypermethylation and reactivation of silenced genes were inconclusive [100,101].

3.7. Anti-Metabolic Syndrome Effects

Metabolic syndrome consists of obesity, high blood pressure, hyperglycemia, and dyslipidemia. GTCs have been reported to have preventive effects against such conditions and medical disorders [102].
It was demonstrated that dietary EGCG reduced body weight in mice with an increase of fecal lipids, attenuation of insulin resistance, and a decrease of plasma cholesterol. The anti-obesity effects of green tea were also shown in human intervention studies [103]. Recently, metabolic syndrome is recognized as a major risk factor for various types of cancer [104]. GTCs are considered to possibly ameliorate the condition of metabolic syndrome, which leads to prevention of carcinogenesis. This possibility is well documented and reviewed in previous publications [105–107].

| Table 1. Possible anti-cancer mechanisms of green tea catechins and their references. |
|-----------------------------------|------------------|
| Mechanisms                        | References       |
| Anti-oxidant activity             | [16,60]          |
| Pro-oxidant activity              | [11,16]          |
| Induction of apoptosis and cell cycle arrest | [11,44,49,63–65] |
| Inhibition of transcriptional factors | [18,33,44,67–71] |
| Inhibition of receptor tyrosine kinase pathways | [33,34,44,45,49,54,64,71,79–86] |
| Modulation of immune system       | [22,88,89,91–93] |
| Epigenetic alteration             | [94,96–99]       |
| Anti-metabolic syndrome effects    | [13,105–107]     |

4. Conclusions

Anti-cancer functions and the molecular mechanisms of GTCs, especially EGCG, have been found in various kinds of animal models and in vitro experiments using different types of cancer cells. In addition, findings in a number of epidemiological and interventional studies have indicated that green tea administration exhibits clinical relevance and significant effects in cancer chemoprevention [108].

Considering the observations in in vivo examinations and clinical investigations, the bioavailability of GTCs following consumption are critical factors [109]. The absorption, distribution, and metabolism of GTCs in humans should also be taken into account. EGCG concentrations for exerting biological effects in several cell culture experiments were much greater than those in the tissue and plasma detected in human trials and animal experiments [89]. In fact, typical tea consumption usually has catechins reach plasma levels only into the low micro-molar range [110]. Therefore, it still remains unclear whether the observations in in vitro studies with high concentrations of EGCG are able to be directly extrapolated to cancer chemoprevention in animals and humans. Recently, various forms of tea catechins, such as pills and capsules, have been investigated to obtain higher concentrations of tea catechins in the tissues and plasma and to enhance their bioavailability [111,112].

The present review summarizes the effects of GTCs against cancer mediated through diverse mechanisms, including anti-oxidant and anti-inflammation activities, immune and epigenetic modification, and RTKs inhibition. There also appear to be reported anti-cancer effects of GTCs other than the ones described in this review. The research area is quite broad, and researchers have not yet fully grasped their mechanisms. To explicate the molecular mechanisms and account for the discrepancy between laboratory examinations and clinical studies, researchers should keep investigating the effects of tea catechins on prevention and treatment of malignancies.

Author Contributions: Conceptualization, Y.S. and M.S.; Writing–original draft Preparation, Y.S.; Writing–review and editing, Y.S. and M.S.; Supervision, M.S.

Funding: This work is supported by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (Grant No. 16K19336, 16K09352, and 18K07968).

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

ACF aberrant crypt foci
AOM azoxymethane
AP-1 activator protein-1
BCAC β-catenin accumulated crypt
DSS dextran sodium sulfate
EC (−)-epicatechin
ECG (−)-epicatechin-3-gallate
EGC (−)-epigallocatechin
EGCG (−)-epigallocatechin-3-gallate
EGFR epidermal growth factor receptor
ERK extracellular signal-regulated kinase
GTC green tea catechin
HNSCC head and neck squamous carcinoma
IDO indoleamine 2,3-dioxygenase
IGF insulin like growth factor
MAPK mitogen-activated protein kinase
1-MT 1-methyltryptophan
NF-κB nuclear factor-κB
NSCLC non-small cell lung cancer
PI3K phosphatidylinositol 3-kinase
PolyE Polyphenon E
RAR retinoic acid receptor
ROS reactive oxygen species
RTK receptor tyrosine kinase
STAT signal transducer and activator of transcription
TNF tumor necrosis factor
TRAMP transgenic adenocarcinoma of the mouse prostate
VEGF vascular endothelial growth factor

References

1. Larsen, C.A.; Dashwood, R.H.; Bisson, W.H. Tea catechins as inhibitors of receptor tyrosine kinases: Mechanistic insights and human relevance. Pharmacol. Res. 2010, 62, 457–464. [CrossRef] [PubMed]
2. Siddiqui, I.A.; Asim, M.; Hafeez, B.B.; Adhami, V.M.; Tarapore, R.S.; Mukhtar, H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011, 25, 1198–1207. [CrossRef] [PubMed]
3. Cabrera, C.; Gimenez, R.; Lopez, M.C. Determination of tea components with antioxidant activity. J. Agric. Food Chem. 2003, 51, 4427–4435. [CrossRef] [PubMed]
4. Graham, H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med. 1992, 21, 334–350. [CrossRef]
5. Katiyar, S.K.; Agarwal, R.; Mukhtar, H. Green tea in chemoprevention of cancer. Compr. Ther. 1992, 18, 3–8. [PubMed]
6. Basu, A.; Lucas, E.A. Mechanisms and effects of green tea on cardiovascular health. Nutr. Rev. 2007, 65, 361–375. [CrossRef] [PubMed]
7. Siddiqui, I.A.; Adhami, V.M.; Saleem, M.; Mukhtar, H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 2006, 50, 130–143. [CrossRef] [PubMed]
8. Grove, K.A.; Lambert, J.D. Laboratory, epidemiological, and human intervention studies show that tea (camellia sinensis) may be useful in the prevention of obesity. J. Nutr. 2010, 140, 446–453. [CrossRef] [PubMed]
9. Khan, N.; Afaq, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res. 2006, 66, 2500–2505. [CrossRef] [PubMed]
10. Mak, J.C. Potential role of green tea catechins in various disease therapies: Progress and promise. Clin. Exp. Pharmacol. Physiol. 2012, 39, 265–273. [CrossRef] [PubMed]

11. Shankar, S.; Ganapathy, S.; Hingorani, S.R.; Srivastava, R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci. 2008, 13, 440–452. [CrossRef] [PubMed]

12. Imai, K.; Suga, K.; Nakachi, K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med. 1997, 26, 769–775. [CrossRef] [PubMed]

13. Nakachi, K.; Suemasu, K.; Suga, K.; Takeo, T.; Imai, K.; Higashi, Y. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn. J. Cancer Res. 1998, 89, 254–261. [CrossRef] [PubMed]

14. Yang, C.S.; Wang, H.; Li, G.X.; Yang, Z.; Guan, F.; Jin, H. Cancer prevention by tea: Evidence from laboratory studies. PharmacoL Res. 2011, 64, 113–122. [CrossRef] [PubMed]

15. Yuan, J.M.; Sun, C.; Butler, L.M. Tea and cancer prevention: Epidemiological studies. PharmacoL Res. 2011, 64, 123–135. [CrossRef] [PubMed]

16. Lambert, J.D.; Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: A role in cancer prevention. Arch. Biochem. Biophys. 2010, 501, 65–72. [CrossRef] [PubMed]

17. Thawonsuwan, J.; Kiron, V.; Satoh, S.; Panigrahi, A.; Verlhac, V. Epigallocatechin-3-gallate (EGCG) affects the antioxidant and immune defense of the rainbow trout, Oncorhynchus mykiss. Fish Physiol. Biochem. 2010, 36, 687–697. [CrossRef] [PubMed]

18. Gupta, S.; Hastak, K.; Afaq, F.; Ahmad, N.; Mukhtar, H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor κB and induction of apoptosis. Oncogene 2004, 23, 2507–2522. [CrossRef] [PubMed]

19. Lee, A.H.; Fraser, M.L.; Binns, C.W. Possible role for green tea in ovarian cancer prevention. Future Oncol. 2005, 1, 771–777. [CrossRef] [PubMed]

20. Shimizu, M.; Adachi, S.; Masuda, M.; Kozawa, O.; Moriwaki, H. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol. Nutr. Food Res. 2011, 55, 832–843. [CrossRef] [PubMed]

21. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82, 1807–1821. [CrossRef] [PubMed]

22. Butt, M.S.; Sultan, M.T. Green tea: Nature’s defense against malignancies. Crit. Rev. Food Sci. Nutr. 2009, 49, 463–473. [CrossRef] [PubMed]

23. Lambert, J.D.; Yang, C.S. Mechanisms of cancer prevention by tea constituents. J. Nutr. 2003, 133, 3262S–3267S. [CrossRef] [PubMed]

24. Shukla, Y. Tea and cancer chemoprevention: A comprehensive review. Asian Pac. J. Cancer Prev. 2007, 8, 155–166. [PubMed]

25. Sadava, D.; Whitlock, E.; Kane, S.E. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Commun. 2007, 360, 233–237. [CrossRef] [PubMed]

26. Milligan, S.A.; Burke, P.; Coleman, D.T.; Bigelow, R.L.; Steffan, J.J.; Carroll, J.L.; Williams, B.J.; Cardelli, J.A. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res. 2009, 15, 4885–4894. [CrossRef] [PubMed]

27. Shim, J.H.; Su, Z.Y.; Chae, J.I.; Kim, D.J.; Zhu, F.; Ma, W.Y.; Bode, A.M.; Yang, C.S.; Dong, Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev. Res. 2010, 3, 670–679. [CrossRef] [PubMed]

28. Liao, J.; Yang, G.Y.; Park, E.S.; Meng, X.; Sun, Y.; Jia, D.; Seril, D.N.; Yang, C.S. Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. Nutr. Cancer 2004, 48, 44–53. [CrossRef] [PubMed]

29. Lu, G.; Liao, J.; Yang, G.; Reuhl, K.R.; Hao, X.; Yang, C.S. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigensis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006, 66, 11944–11501. [CrossRef] [PubMed]

30. Manna, S.; Mukherjee, S.; Roy, A.; Das, S.; Panda, C.K. Tea polyphenols can restrict benzo[a]pyrene-induced lung carcinogenesis by altered expression of p53-associated genes and H-ras, c-myc and cyclin D1. J. Nutr. Biochem. 2009, 20, 337–349. [CrossRef] [PubMed]
31. Mimoto, J.; Kiura, K.; Matsu, K.; Yoshino, T.; Takata, I.; Ueoka, H.; Kataoka, M.; Harada, M. (−)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. *Carcinogenesis* 2000, 21, 915–919. [CrossRef] [PubMed]

32. Wang, Z.Y.; Hong, J.Y.; Huang, M.T.; Reuhl, K.R.; Conney, A.H.; Yang, C.S. Inhibition of N-nitrosodimethylamine- and (4-methylnitrosamino)-1-(3-pyridyl)-1-butane-induced tumorigenesis in A/J mice by green tea and black tea. *Cancer Res.* 1992, 52, 1943–1947. [PubMed]

33. Masuda, M.; Suzui, M.; Lim, J.T.; Deguchi, A.; Soh, J.W.; Weinstein, I.B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. *J. Exp. Ther. Oncol.* 2002, 2, 350–359. [CrossRef] [PubMed]

34. Sartippour, M.R.; Shao, Z.M.; Heber, D.; Beatty, P.; Zhang, L.; Liu, C.; Ellis, L.; Liu, W.; Go, V.L.; Brooks, M.N. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. *J. Nutr.* 2002, 132, 2307–2311. [CrossRef] [PubMed]

35. Araki, H.; Shidoji, Y.; Yamada, Y.; Mori, K.; Muto, Y. Retinoid agonist activities of synthetic geranyl geraniolic acid derivatives. *Biochem. Biophys. Res. Commun.* 1995, 209, 66–72. [CrossRef] [PubMed]

36. Farabegoli, F.; Papi, A.; Orlandi, M. (−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. *Biosci. Rep.* 2011, 31, 99–108. [CrossRef] [PubMed]

37. Hsieh, T.C.; Wu, J.M. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. *Int. J. Oncol.* 2003, 23, 851–859. [PubMed]

38. Thangapazham, R.L.; Singh, K.; Maheshwari, R.K. Green tea polyphenols and its constituent epigallocatechin gallate elicits anti-angiogenic response in human breast cancer cells in vitro and in vivo. *Cancer Lett.* 2007, 245, 232–241. [CrossRef] [PubMed]

39. Kavanagh, K.T.; Hafer, L.J.; Kim, D.W.; Mann, K.K.; Sherr, D.H.; Rogers, A.E.; Sonenshein, G.E. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. *J. Cell Biochem.* 2001, 82, 387–398. [CrossRef] [PubMed]

40. Lubet, R.A.; Yang, C.S.; Lee, M.J.; Harra, Y.; Kapetanovic, I.M.; Crowell, J.A.; Steele, V.E.; Juliana, M.M.; Grubbs, C.J. Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols. *Mol. Cancer Ther.* 2007, 6, 2022–2028. [CrossRef] [PubMed]

41. Jia, X.; Han, C. Effects of green tea on colonic aberrant crypt foci and proliferative indexes in rats. *Nutr. Cancer* 2001, 39, 239–243. [CrossRef] [PubMed]

42. Ohishi, T.; Kishimoto, Y.; Miura, N.; Shiota, G.; Kohri, T.; Harra, Y.; Hasegawa, J.; Isemura, M. Synergistic effects of (−)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. *Cancer Lett.* 2002, 177, 49–56. [CrossRef]

43. Shimizu, M.; Shirakami, Y.; Tsurumi, H.; Harra, Y.; Tanaka, T.; Mori, H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. *Mol. Med. Rep.* 2008, 1, 355–361. [CrossRef] [PubMed]
49. Shimizu, M.; Shirakami, Y.; Sakai, H.; Adachi, S.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H.
(−)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/6J-Ksj-db/db mice. Cancer Prev. Res. 2008, 1, 298–304. [CrossRef] [PubMed]

50. Siddiqui, I.A.; Malik, A.; Adhami, V.M.; Asim, M.; Hafeez, B.B.; Sarfaraz, S.; Mukhtar, H. Green tea
polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis
and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008,
27, 2055–2063. [CrossRef] [PubMed]

51. Lee, S.C.; Chan, W.K.; Lee, T.W.; Lam, W.H.; Wang, X.; Chan, T.H.; Wong, Y.C. Effect of a prodrug of the
green tea polyphenol (−)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer
in vivo. Nutr. Cancer 2008, 60, 483–491. [CrossRef] [PubMed]

52. Liao, S.; Umekita, Y.; Guo, J.; Kokontis, J.M.; Hiipakka, R.A. Growth inhibition and regression of human
prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995, 96, 239–243.

53. Roomi, M.W.; Ivanov, V.; Kalinovsky, T.; Niedzwiecki, A.; Rath, M. In vivo antitumor effect of ascorbic acid,
lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: Evaluation of
tumor growth and immunohistochemistry. In Vivo 2005, 19, 179–183. [PubMed]

54. Gupta, S.; Hastak, K.; Ahmad, N.; Lewin, J.S.; Mukhtar, H. Inhibition of prostate carcinogenesis in TRAMP
mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. USA 2001, 98, 10350–10355. [CrossRef]
[PubMed]

55.Caporali, A.; Davalli, P.; Astancolle, S.; D’Arca, D.; Brausi, M.; Bettuzzi, S.; Corti, A. The chemopreventive
action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin
over-expression. Carcinogenesis 2004, 25, 2217–2224. [CrossRef] [PubMed]

56. Zaveri, N.T. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications.
Life Sci. 2006, 78, 2073–2080. [CrossRef] [PubMed]

57. Zheng, L.T.; Ryu, G.M.; Kwon, B.M.; Lee, W.H.; Suk, K. Anti-inflammatory effects of catechols in
lipopolysaccharide-stimulated microglia cells: Inhibition of microglial neurotoxicity. Eur. J. Pharmacol.
2008, 588, 106–113. [CrossRef] [PubMed]

58. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like
growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of
hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 2004, 68, 1003–1015. [CrossRef]
[PubMed]

59. Mukhtar, H.; Ahmad, N. Tea polyphenols: Prevention of cancer and optimizing health. Am. J. Clin. Nutr.
2000, 71, 1698S–1702S. [CrossRef] [PubMed]

60. Sridvidhya, R.; Jythihalakshmi, V.; Arulmathi, K.; Senthilkumaran, V.; Kalaiselvi, P. Attenuation of
senescence-induced oxidative exacerbations in aged rat brain by (−)-epigallocatechin-3-gallate. Int. J.
Dev. Neurosci. 2008, 26, 217–223. [CrossRef] [PubMed]

61. Ellinger, S.; Muller, N.; Stehle, P.; Ulrich-Merzenich, G. Consumption of green tea or green tea products:
Is there an evidence for antioxidant effects from controlled interventional studies? Phytomedicine 2011,
18, 903–915. [CrossRef] [PubMed]

62. Mohamed, M.S.; Bishr, M.K.; Almutairi, F.M.; Ali, A.G. Inhibitors of apoptosis: Clinical implications in
cancer. Apoptosis 2017, 22, 1487–1509. [CrossRef] [PubMed]

63. Shankar, S.; Suthakar, G.; Srivastava, R.K. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis
in pancreatic cancer. Front. Biosci. 2007, 12, 5039–5051. [CrossRef] [PubMed]

64. Masuda, M.; Suzuki, M.; Weinstein, I.B. Effects of epigallocatechin-3-gallate on growth, epithelial growth
factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck
squamous cell carcinoma cell lines. Clin. Cancer Res. 2001, 7, 4220–4229. [PubMed]

65. Smith, D.M.; Wang, Z.; Kazi, A.; Li, L.H.; Chan, T.H.; Dou, Q.P. Synthetic analogs of green tea polyphenols as
proteasome inhibitors. Mol. Med. 2002, 8, 382–392. [PubMed]

66. Kaltschmidt, B.; Greiner, J.E.W.; Kadhim, H.M.; Kaltschmidt, C. Subunit-specific role of NF-κB in cancer.
Biomedicines 2018, 6, 44. [CrossRef] [PubMed]

67. Fujiki, H.; Suganuma, M.; Okabe, S.; Sueoka, N.; Komori, A.; Sueoka, E.; Kozu, T.; Tada, Y.; Suga, K.;
Imai, K.; et al. Cancer inhibition by green tea. Mutat. Res. 1998, 402, 307–310. [CrossRef]
68. Ahmed, S.; Wang, N.; Lalonde, M.; Goldberg, V.M.; Haqqi, T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 767–773. [CrossRef] [PubMed]

69. Chung, J.Y.; Huang, C.; Meng, X.; Dong, Z.; Yang, C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved. *Cancer Res.* **1999**, *59*, 4610–4617. [PubMed]

70. Dong, Z.; Ma, W.; Huang, C.; Yang, C.S. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (−)-epigallocatechin gallate, and theaflavins. *Cancer Res.* **1997**, *57*, 4414–4419. [PubMed]

71. Shimizu, M.; Deguchi, A.; Joe, A.K.; Moriwaki, H.; Weinstein, I.B. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. *J. Exp. Ther. Oncol.* **2005**, *5*, 69–78. [PubMed]

72. Shimizu, M.; Shirakami, Y.; Moriwaki, H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. *Int. J. Mol. Sci.* **2008**, *9*, 1034–1049. [CrossRef] [PubMed]

73. Shimizu, M.; Weinstein, I.B. Modulation of signal transduction by tea catechins and related phytochemicals. *Mutat. Res.* **2005**, *591*, 147–160. [CrossRef] [PubMed]

74. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. *Cell* **2010**, *141*, 1117–1134. [CrossRef] [PubMed]

75. Schlessinger, J. Cell signaling by receptor tyrosine kinases. *Cell* **2000**, *103*, 211–225. [CrossRef]

76. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. *Nat. Rev. Cancer* **2005**, *5*, 341–354. [CrossRef] [PubMed]

77. Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. *Nat. Rev. Cancer* **2004**, *4*, 505–518. [CrossRef] [PubMed]

78. Press, M.F.; Lenz, H.J. EGFR, HER2 and VEGF pathways: Validated targets for cancer treatment. *Drugs* **2007**, *67*, 2045–2075. [CrossRef] [PubMed]

79. Lee, Y.K.; Bone, N.D.; Strege, A.K.; Shanafelt, T.D.; Jelinek, D.F.; Kay, N.E. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. *Blood* **2004**, *104*, 788–794. [CrossRef] [PubMed]

80. Shirakami, Y.; Shimizu, M.; Adachi, S.; Sakai, H.; Nakagawa, T.; Yasuda, Y.; Tsurumi, H.; Hara, Y.; Moriwaki, H. (−)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. *Cancer Sci.* **2009**, *100*, 1957–1962. [CrossRef] [PubMed]

81. Shimizu, M.; Deguchi, A.; Joe, A.K.; McKoy, J.F.; Moriwaki, H.; Weinstein, I.B. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. *Biochem. Biophys. Res. Commun.* **2008**, *374*, 1957–1962. [CrossRef] [PubMed]

82. Chen, J.Y.; Huang, C.; Meng, X.; Dong, Z.; Yang, C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved. *Cancer Res.* **1999**, *59*, 4610–4617. [PubMed]

83. Ahmed, S.; Wang, N.; Lalonde, M.; Goldberg, V.M.; Haqqi, T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 767–773. [CrossRef] [PubMed]

84. Adachi, S.; Nagao, T.; To, S.; Joe, A.K.; Shimizu, M.; Matsushima-Nishiwaki, R.; Kozawa, O.; Moriwaki, H.; Maxfield, F.R.; Weinstein, I.B. (−)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. *Carcinogenesis* **1999**, *20*, 1986–1993. [CrossRef] [PubMed]

85. Adachi, S.; Shimizu, M.; Shirakami, Y.; Yamauchi, J.; Natsume, H.; Matsushima-Nishiwaki, R.; To, S.; Weinstein, I.B.; Moriwaki, H.; Kozawa, O. (−)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. *Carcinogenesis* **2009**, *30*, 1544–1552. [CrossRef] [PubMed]
87. Little, T.J.; Hultmark, D.; Read, A.F. Invertebrate immunity and the limits of mechanistic immunology. *Nat. Immunol.* 2005, 6, 651–654. [CrossRef] [PubMed]

88. Klein, C.; Sato, T.; Meguid, M.M.; Miyata, G. From food to nutritional support to specific nutraceuticals: A journey across time in the treatment of disease. *J. Gastroenterol.* 2000, 35 (Suppl. 12), 1–6. [PubMed]

89. Yang, F.; de Villiers, W.J.; McClain, C.J.; Varilek, G.W. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. *J. Nutr.* 1998, 128, 2334–2340. [CrossRef] [PubMed]

90. Liu, X.; Newton, R.C.; Friedman, S.M.; Scherle, P.A. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. *Curr. Cancer Drug Targets* 2009, 9, 938–952. [CrossRef] [PubMed]

91. Cheng, C.W.; Shieh, P.C.; Lin, Y.C.; Chen, Y.J.; Lin, Y.H.; Kuo, D.H.; Liu, J.Y.; Kao, J.Y.; Kao, M.C.; Way, T.D. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (−)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. *J. Agric. Food Chem.* 2010, 58, 887–894. [CrossRef] [PubMed]

92. Ogawa, K.; Hará, T.; Shimizu, M.; Nagano, J.; Ohno, T.; Hoshi, M.; Ito, H.; Tsurumi, H.; Saito, K.; Seishima, M.; et al. (−)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. *OncoLett.* 2012, 4, 546–550. [CrossRef] [PubMed]

93. Ogawa, K.; Hará, T.; Shimizu, M.; Ninomiya, S.; Nagano, J.; Sakai, H.; Hoshi, M.; Ito, H.; Tsurumi, H.; Saito, K.; et al. Suppression of azoxymethane-induced colorectal preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. *Cancer Sci.* 2012, 103, 951–958. [CrossRef] [PubMed]

94. Link, A.; Balagué, F.; Goel, A. Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics. *Biochem. Pharmacol.* 2010, 80, 1771–1792. [CrossRef] [PubMed]

95. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. *Nat. Rev. Cancer* 2004, 4, 143–153. [CrossRef] [PubMed]

96. Fang, M.Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C.S. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res.* 2003, 63, 7563–7570. [PubMed]

97. Choi, K.C.; Jung, M.G.; Lee, Y.H.; Yoon, J.C.; Kwon, S.H.; Kim, M.J.; Cha, J.H.; Kim, Y.J.; Jun, W.J.; et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. *Cancer Res.* 2009, 69, 583–592. [CrossRef] [PubMed]

98. Fang, M.; Chen, D.; Yang, C.S. Dietary polyphenols may affect DNA methylation. *J. Nutr.* 2007, 137, 2235–2285. [CrossRef] [PubMed]

99. Guilleret, I.; Benhattar, J. Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. *Biochem. Biophys. Res. Commun.* 2004, 325, 1037–1043. [CrossRef] [PubMed]

100. Morey Kinney, S.R.; Zhang, W.; Pascual, M.; Greally, J.M.; Gillard, B.M.; Karasik, E.; Foster, B.A.; Karpf, A.R. Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate. *Cancer Prev. Res.* 2009, 2, 1065–1075. [CrossRef] [PubMed]

101. Tsao, A.S.; Liu, D.; Martin, J.; Tang, X.M.; Lee, J.J.; El-Naggar, A.K.; Wistuba, I.; Culotta, K.S.; Mao, L.; Gillenwater, A.; et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. *Cancer Prev. Res.* 2009, 2, 931–941. [CrossRef] [PubMed]

102. Bose, M.; Lambert, J.D.; Ju, J.; Reubl, K.R.; Shaptes, S.A.; Yang, C.S. The major green tea polyphenol, (−)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. *J. Nutr.* 2008, 138, 1677–1683. [CrossRef] [PubMed]

103. Huang, J.; Wang, Y.; Xie, Z.; Zhou, Y.; Zhang, Y.; Wan, X. The anti-obesity effects of green tea in human intervention and basic molecular studies. *Eur. J. Clin. Nutr.* 2014, 68, 1075–1087. [CrossRef] [PubMed]

104. Mendonca, F.M.; de Sousa, F.R.; Barbosa, A.L.; Martins, S.C.; Araujo, R.L.; Soares, R.; Abreu, C. Metabolic syndrome and risk of cancer: Which link? *Metabolism* 2015, 64, 182–189. [CrossRef] [PubMed]

105. Shirakami, Y.; Ohnishi, M.; Sakai, H.; Tanaka, T.; Shimizu, M. Prevention of colorectal cancer by targeting obesity-related disorders and inflammation. *Int. J. Mol. Sci.* 2017, 18, 908. [CrossRef] [PubMed]

106. Sakai, H.; Shirakami, Y.; Shimizu, M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. *World J. Gastroenterol.* 2016, 22, 394–406. [CrossRef] [PubMed]
107. Shirakami, Y.; Shimizu, M.; Kubota, M.; Araki, H.; Tanaka, T.; Moriwaki, H.; Seishima, M. Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities. *World J. Gastroenterol.* 2014, 20, 8939–8946. [PubMed]

108. Shirakami, Y.; Sakai, H.; Kochi, T.; Seishima, M.; Shimizu, M. Catechins and its role in chronic diseases. *Adv. Exp. Med. Biol.* 2016, 929, 67–90. [PubMed]

109. Lee, M.J.; Wang, Z.Y.; Li, H.; Chen, L.; Sun, Y.; Gobbo, S.; Balentine, D.A.; Yang, C.S. Analysis of plasma and urinary tea polyphenols in human subjects. *Cancer Epidemiol. Biomarkers Prev.* 1995, 4, 393–399. [PubMed]

110. Yang, C.S.; Sang, S.; Lambert, J.D.; Lee, M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. *Mol. Nutr. Food Res.* 2008, 52 (Suppl. 1), S139–S151. [CrossRef] [PubMed]

111. Jimenez-Saenz, M.; Martinez-Sanchez Mdel, C. Acute hepatitis associated with the use of green tea infusions. *J. Hepatol.* 2006, 44, 616–617. [CrossRef] [PubMed]

112. Hu, B.; Liu, X.; Zhang, C.; Zeng, X. Food macromolecule based nanodelivery systems for enhancing the bioavailability of polyphenols. *J. Food Drug Anal.* 2017, 25, 3–15. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).